GeneHealth - Your precision medicine

Childhood Hypophosphatasia

Disease Details

Family Health Simplified

Buy Membership

Description: Childhood hypophosphatasia is a rare genetic disorder characterized by defective bone mineralization, leading to skeletal abnormalities and dental issues.
Type: Childhood hypophosphatasia is typically inherited in an autosomal recessive manner.
Signs And Symptoms: Childhood hypophosphatasia is a rare metabolic bone disorder caused by deficient activity of the enzyme alkaline phosphatase.

Signs and symptoms may include:

1. **Bone and Skeletal Issues:**
- Rickets (soft, weak bones)
- Bone pain
- Delayed walking
- Premature loss of primary (baby) teeth with intact roots

2. **Muscle Weakness:**
- Generalized weakness
- Difficulty with gross motor skills

3. **Respiratory Problems:**
- Weakness of respiratory muscles, leading to breathing difficulties

4. **Growth Delays:**
- Short stature or failure to thrive
- Delayed milestones

5. **Neurological Issues:**
- Craniosynostosis (premature fusion of skull bones)
- Increased intracranial pressure

Note that the severity of symptoms can vary widely among individuals with childhood hypophosphatasia.
Prognosis: Childhood hypophosphatasia is a rare inherited disorder that affects the development of bones and teeth. The prognosis can vary widely depending on the severity of the condition. In milder cases, children may experience only dental abnormalities or minor skeletal issues, while in more severe cases, they can suffer from significant skeletal deformities, growth retardation, and other complications. With advances in treatments, including enzyme replacement therapy, the outlook has improved for many affected individuals, but close medical management remains crucial.
Onset: Childhood hypophosphatasia typically has an onset during early childhood, often between the ages of 1 and 10. Symptoms can include premature loss of primary (baby) teeth, short stature, delayed walking, and a waddling gait due to weakened bones.
Prevalence: The prevalence of childhood hypophosphatasia is estimated to be around 1 in 100,000 to 1 in 300,000 live births.
Epidemiology: Childhood hypophosphatasia is a rare, inherited metabolic bone disease that affects the development of bones and teeth. It occurs due to mutations in the ALPL gene, which encodes the tissue-nonspecific alkaline phosphatase (TNSALP) enzyme. The exact prevalence is not well-established but is estimated to range from 1 in 100,000 to 1 in 300,000 live births globally. The condition is more frequently identified in populations with higher rates of consanguinity.
Intractability: Childhood hypophosphatasia can be challenging to treat, but it is not entirely intractable. Advances in medical treatments, such as enzyme replacement therapy with asfotase alfa, have shown promise in managing symptoms and improving outcomes. However, the effectiveness of treatments can vary depending on the severity of the disease and the individual patient. Early diagnosis and ongoing management by a multidisciplinary team are crucial for optimizing the quality of life for affected children.
Disease Severity: Childhood hypophosphatasia is a rare genetic disorder characterized by defective bone mineralization and a deficiency in the enzyme alkaline phosphatase. The disease severity can vary widely, ranging from mild forms, where symptoms may include premature loss of primary teeth without significant bone abnormalities, to more severe forms where there can be significant skeletal deformities, growth retardation, and muscular weakness. In severe cases, respiratory complications can occur due to weakened chest muscles and malformed ribs, potentially leading to life-threatening situations.
Healthcare Professionals: Disease Ontology ID - DOID:0110915
Pathophysiology: Childhood hypophosphatasia is a rare inherited metabolic disorder affecting bone and tooth mineralization. It results from mutations in the ALPL gene, which encodes the enzyme alkaline phosphatase. This enzyme is crucial for bone mineralization as it breaks down pyrophosphate, a molecule that inhibits the formation of hydroxyapatite crystals. Without sufficient alkaline phosphatase activity, pyrophosphate accumulates, preventing normal bone and tooth mineralization and leading to the skeletal abnormalities characteristic of hypophosphatasia. Symptoms in childhood can include premature loss of teeth, short stature, bone pain, and fractures.
Carrier Status: Carrier status for childhood hypophosphatasia is typically assessed by genetic testing. Hypophosphatasia is an inherited disorder caused by mutations in the ALPL gene. Carriers, individuals with one copy of a mutated gene and one normal gene, usually do not show symptoms but can pass the mutation on to their offspring.
Mechanism: Childhood hypophosphatasia is a rare genetic disorder characterized by defective bone mineralization and a deficiency in the enzyme alkaline phosphatase. It is caused by mutations in the ALPL gene, which encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP).

The molecular mechanisms underlying childhood hypophosphatasia involve:

1. **ALPL Gene Mutations**: These mutations lead to either decreased production or impaired function of TNSALP. Over 300 different mutations have been identified, which can affect the stability, folding, or activity of the enzyme.

2. **Enzyme Deficiency**: TNSALP is crucial for the hydrolysis of phosphate compounds, such as pyridoxal 5'-phosphate (PLP) and inorganic pyrophosphate (PPi). PLP is the active form of vitamin B6, essential for many biochemical processes, including neurotransmitter synthesis. PPi is a potent inhibitor of mineralization.

3. **Substrate Accumulation**: Due to deficient TNSALP activity, substrates like PPi and PLP accumulate. Elevated PPi levels inhibit hydroxyapatite crystal formation, a necessary step in bone mineralization. This results in rickets in children, which is characterized by bone pain, deformities, and growth retardation.

4. **Systemic Effects**: Accumulation of PLP can affect vitamin B6 metabolism, leading to other symptoms such as seizures.

Overall, hypophosphatasia has a profound impact on skeletal and systemic health due to its disruption of key enzymatic processes critical for bone formation and metabolic functions.
Treatment: Hypophosphatasia is a rare genetic disorder affecting bone mineralization. For childhood hypophosphatasia, treatment strategies may include:

1. **Asfotase alfa (Strensiq)**: An enzyme replacement therapy specifically approved for treating perinatal, infantile, and juvenile-onset hypophosphatasia.
2. **Supportive care**: Pain management, physical therapy to improve mobility and muscle strength.
3. **Orthopedic management**: For fractures and deformities.
4. **Dental care**: Addressing early loss of teeth, a common symptom.

Treatment is highly individualized based on disease severity and symptoms. Regular follow-up with a healthcare provider specializing in metabolic bone disorders is crucial.
Compassionate Use Treatment: For childhood hypophosphatasia, compassionate use treatment typically involves the administration of asfotase alfa, an enzyme replacement therapy. This treatment is FDA-approved but might be accessible on a compassionate use basis in certain countries or scenarios.

Off-label or experimental treatments for hypophosphatasia may include:

1. **Teriparatide**: Although approved for osteoporosis, teriparatide has been used off-label to stimulate bone formation in some patients with hypophosphatasia.
2. **Vitamin B6**: This is sometimes administered to manage seizures associated with the disease, as these seizures can be refractory to other treatments.
3. **Stem Cell Therapy**: Experimental approaches using stem cells to promote bone regeneration are being investigated in clinical trials.

Always consult a healthcare professional for the most appropriate treatment options.
Lifestyle Recommendations: For childhood hypophosphatasia, key lifestyle recommendations include:

1. **Physical Activity:**
- Engage in low-impact exercises to strengthen muscles and maintain mobility while minimizing stress on bones.
- Swimming and walking are good options.

2. **Diet:**
- Ensure a balanced diet rich in nutrients, particularly calcium and vitamin D, to support bone health.
- Avoid excessive intake of foods or drinks that can weaken bones, such as those high in phosphate additives (like soda).

3. **Sun Exposure:**
- Moderate sun exposure to boost natural vitamin D synthesis, but avoid overexposure to prevent skin damage.

4. **Orthopedic Considerations:**
- Regular monitoring by healthcare professionals, such as endocrinologists and orthopedic surgeons, to track bone health.
- Use of braces or other support devices if needed to help with walking and posture.

5. **Pain Management:**
- Utilize pain management strategies as recommended by healthcare providers, which may include physical therapy, medications, or other interventions.

6. **Regular Medical Follow-up:**
- Keep regular appointments with healthcare providers for ongoing assessment and management of the condition.

7. **Psychosocial Support:**
- Seek counseling or support groups to help with the emotional and social challenges of living with a chronic condition.

These lifestyle modifications aimed at managing childhood hypophosphatasia should always be tailored to the individual needs of the child and under the guidance of a healthcare professional.
Medication: Childhood hypophosphatasia is treated using enzyme replacement therapy (ERT). The specific medication used for ERT is asfotase alfa, marketed under the name Strensiq. This medication is designed to replace the deficient enzyme alkaline phosphatase in the body, which improves bone mineralization and helps manage symptoms of the disease.
Repurposable Drugs: For childhood hypophosphatasia, asfotase alfa (Strensiq) is a primary treatment specifically approved for the disease. There are no widely recognized repurposable drugs for this condition known at this time. The focus remains on enzyme replacement therapy to address the underlying cause of the disease.
Metabolites: Childhood hypophosphatasia is a rare metabolic bone disorder characterized by defective bone mineralization and deficiency in the enzyme alkaline phosphatase. Key metabolites involved in hypophosphatasia include:

1. **Inorganic Pyrophosphate (PPi)** - Elevated levels due to defective degradation by alkaline phosphatase.
2. **Pyridoxal 5'-phosphate (PLP)** - Increased levels since alkaline phosphatase is required for its metabolism.
3. **Phosphoethanolamine (PEA)** - Elevated in blood and urine due to inadequate breakdown.

These metabolites are critical markers for diagnosing and understanding the disease progression in hypophosphatasia.
Nutraceuticals: Childhood hypophosphatasia is a rare genetic disorder affecting bone mineralization due to deficient activity of the enzyme alkaline phosphatase. Nutraceuticals, such as vitamin D, calcium, and magnesium, are often considered to support bone health. However, the efficacy in treating hypophosphatasia is limited and should be used under medical guidance. The main treatment focuses on enzyme replacement therapy and supportive care. Nutraceuticals can complement but not replace standard medical treatments. As for information on nanotechnology applications, there is limited data available specifically regarding its use in treating childhood hypophosphatasia.
Peptides: Childhood hypophosphatasia is a rare genetic disorder affecting bone mineralization, caused by mutations in the ALPL gene. Enzyme replacement therapy with asfotase alfa, a recombinant enzyme, has shown promise in treating this condition. Notably, peptides can play a role in modulating this therapy, enhancing the stability and efficacy of the enzyme.